In a recent opinion piece, William Padula emphasizes that the real issue facing gene therapy is not the lack of effective treatments, but rather the absence of a robust financing model.
Padula suggests that without a well-structured system to support the costs associated with these therapies, many patients may not benefit from the available cures.
The call for innovative financing solutions is crucial to ensure that groundbreaking treatments can reach those in need.